Edition:
United States

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.33USD
11 Dec 2017
Change (% chg)

$0.08 (+2.46%)
Prev Close
$3.25
Open
$3.25
Day's High
$3.34
Day's Low
$3.23
Volume
286,127
Avg. Vol
297,442
52-wk High
$4.47
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Amarin reports Q3 loss per share $0.04
Wednesday, 1 Nov 2017 05:30am EDT 

Nov 1 (Reuters) - Amarin :Amarin reports third quarter 2017 financial results and provides update on operations.Q3 loss per share $0.04.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Amarin Corporation Plc - Qtrly net product revenue $47.1 million versus $32.4 million​.  Full Article

Amarin names Mark Salyer chief commercial officer
Wednesday, 13 Sep 2017 06:00am EDT 

Sept 13 (Reuters) - Amarin Corporation Plc :Amarin appoints Mark W. Salyer to new position of chief commercial officer.Amarin remains on track to reach record product revenues of $165 to $175 million in 2017​.Most recently, Salyer was at Teva Pharmaceuticals as executive vice president and general manager of Teva Respiratory LLC​.  Full Article

Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned
Monday, 14 Aug 2017 06:00am EDT 

Aug 14 (Reuters) - Amarin Corporation Plc :Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee.Amarin Corporation says ‍independent data monitoring committee recommended that trial continue as planned without modification​.Says ‍results from completed study are expected in Q2 or Q3 2018​.Says ‍anticipates that onset of approximately 100 pct of events will likely occur in early 2018​.Amarin Corp - ‍interim efficacy analysis performed after adjudication of about 80 pct of target 1,612 aggregate primary cardiovascular events occurred within study​.  Full Article

Amarin reports Q2 loss per share $0.05
Wednesday, 2 Aug 2017 05:30am EDT 

Aug 2 (Reuters) - Amarin Corporation Plc :Amarin reports second quarter 2017 financial results and provides update on operations.Q2 loss per share $0.05.Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Amarin Corporation Plc - ‍Increasing guidance on full year net product revenue to $165-175 million​.Amarin Corporation Plc - ‍Reduce-it cardiovascular outcomes trial continues to progress towards reported results in Q2 or Q3 of 2018​.Qtrly total revenue, net $45.2 million versus $33.1 million.Amarin Corporation Plc - ‍Expects continued trx growth to drive increased full-year 2017 revenue​.Amarin - Anticipates reduce-it study reaching in early 2018 onset of 100% of targeted cumulative total of 1,612 primary major adverse cardiovascular events.  Full Article

Amarin says vascepa showed reductions in potentially atherogenic lipid parameters
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Amarin Corporation Plc :Amarin says vascepa showed reductions in potentially atherogenic lipid parameters in statin-treated women with type 2 diabetes and persistent high triglycerides.Amarin Corp says vascepa significantly increased blood EPA levels.Amarin Corp - efficacy and safety of vascepa 4 g/day in women were consistent with overall anchor study results.Amarin Corp expects trial will run to completion and onset of target final primary cardiovascular event will likely be reached near end of 2017.  Full Article

Amarin Q1 loss per share $0.08
Wednesday, 3 May 2017 05:00am EDT 

May 3 (Reuters) - Amarin Corporation Plc :Amarin reports first quarter 2017 financial results and provides update on operations.Q1 loss per share $0.08.Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.Amarin corporation plc - re-affirms guidance on full year net product revenues of between $155 and $165 million.Amarin corporation plc - reduce-it cardiovascular outcomes trial continues to progress on schedule.Amarin - expects onset of final primary cardiovascular event near end of 2017, with report of top-line results, publications in 2018 for reduce-it trial.Fy2017 revenue view $165.0 million -- Thomson Reuters I/B/E/S.Amarin corporation plc - currently estimate that co will report results of reduce-it in mid-2018, assuming study goes to completion.  Full Article

Amarin reaches the onset of about 80 pct of the target aggregate number within the reduce-it study
Thursday, 16 Mar 2017 05:00am EDT 

Amarin Corporation Plc - : Amarin reaches the onset of approximately 80% of the target aggregate number of primary major adverse cardiovascular events within the reduce-it study . Currently expects independent interim analysis to be conducted before end of third calendar quarter of this year .Amarin says will remain blinded to interim and ongoing results of reduce-it study until ready to be stopped at interim or final analysis.  Full Article

Amarin Corp files for potential mixed shelf - SEC filing
Wednesday, 1 Mar 2017 05:24pm EST 

Amarin Corporation Plc :Amarin Corporation Plc files for potential mixed shelf; size not disclosed - sec filing.  Full Article

Amarin files for resale by the selling shareholders' of up to 10.4 mln shares- SEC filing
Wednesday, 1 Mar 2017 05:22pm EST 

Amarin Corporation Plc :Amarin Corp Plc files for resale by the selling shareholders of up to 10.4 million American Depositary Shares - SEC filing.  Full Article

Amarin reports posts Q4 loss per share $0.10
Tuesday, 28 Feb 2017 06:00am EST 

Amarin Corporation Plc : Amarin reports record fourth quarter and full year 2016 financial results and provides update on operations . Q4 loss per share $0.10 . Q4 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Qtrly total revenue, net $38.7 million versus $26.6 million .In 2017, Amarin anticipates spending approximately $50 million to $60 million for research and development.  Full Article

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations